Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
NCT ID: NCT04128072
Last Updated: 2024-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
43 participants
INTERVENTIONAL
2023-03-07
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The treatment of CTCL is primarily determined by the disease extent. Prolonged complete remissions have been obtained with skin-directed therapies in early stage Mycosis fungoides (MF) (IA-IIA), whereas advanced stages CTCL (IIB-IVB) are often refractory to treatment and, thus, have an unfavorable prognosis.
Currently, there is no standard treatment option for CTCL, especially for advanced stages, and the optimal treatment sequence is still debated with a large variability in the therapeutic approach across countries. Patients with advanced-stage disease or refractory cutaneous CTCL should be treated with systemic therapies and, whenever possible, should be offered to participate in clinical trials. Currently, there is a urgent call for new treatments in CTCL with higher response rate and prolonged time to progression;
In this study, we propose a very innovative treatment schedule in which mogamulizumab is used before Total Skin Electron Beam therapy (TSEB) for systemic disease control and as a maintenance treatment after skin-directed therapy. We hypothesize that our regimen will show a more manageable toxicity profile than a combination treatment and allow for a long-term mogamulizumab administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
NCT06113081
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
NCT02593045
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
NCT06698003
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04082936
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)
Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.
TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week).
Mogamulizumab
• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
Total Skin Electron Beam Therapy (TSEB)
* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).
* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.
* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.
* Mogamulizumab is stopped during TSEB administration.
Mogamulizumab (subsequent cycles post TSEB)
• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.
Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mogamulizumab
• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
Total Skin Electron Beam Therapy (TSEB)
* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).
* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.
* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.
* Mogamulizumab is stopped during TSEB administration.
Mogamulizumab (subsequent cycles post TSEB)
• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.
Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who have failed (refractory or relapsed) at least one prior course of systemic therapy.
* All clinically significant toxic effects of prior cancer therapy to grade ≤ 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE, v.5.0), excluding the specifications required in the criteria 'Adequate haematological and organ function' below
* Males and female subjects ≥ 18 years
* WHO performance status 0-1
* Adequate haematological and organ function:
* absolute neutrophil count (ANC) ≥ 1.0 × 109/L
* platelets ≥ 75 × 109/L (≥ 75,000/mm3)
* bilirubin ≤ 1.5 × upper limit of normal (ULN) except for subjects with Gilbert's syndrome;
* aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN
* serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance \> 50 mL/min using the Cockcroft-Gault formula
* Subjects previously treated with anti-CD4 antibody or alemtuzumab are eligible provided a washout period ≥ 3 months and CD4+ cell counts ≥ 200/mm3
* Clinically normal cardiac function based on 12-lead ECG and above the institutional lower limit of normal for left ventricular ejection fraction assessed either by multi-gated acquisition scan or cardiac ultrasound
* Women of child bearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to the first dose of study treatment
* WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice through abstinence from sexual intercourse during the study and for 6 months after the last dose.
* Male subjects and their female partners of child bearing potential must be willing to use an appropriate method of contraception defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice through abstinence from sexual intercourse (periodic abstinence, e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) during the study and for 6 months after the last dose.
* Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment
* Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations
Exclusion Criteria
* Prior TSEB
* Patients who received localised radiotherapy within 2 weeks prior to registration
* Patients who received any systemic therapy for MF within 4 weeks prior to registration.
Note: In case of rapid progression, if patient has recovered from all toxicities AND last dose occurred more than 5 half lives of the drug/treatment used, patient could be allowed to start earlier after consultation with medical monitor
* History of other malignancy in the past 5 years with the exception of treated carcinoma in situ of the cervix, localized prostate cancer with PSA \<0.1, in-situ melanoma, and non-melanoma skin cancer
* History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
* Known hypersensitivity to CHO cell products or any component of the mogamulizumab formulation (see section 6.1.1)
* Significant uncontrolled intercurrent illness including, but not limited to:
* uncontrolled infection requiring antibiotics;
* clinically significant cardiac disease (class III or IV of the New York Heart Association \[NYHA\] classification);
* unstable angina pectoris;
* angioplasty, stenting, or myocardial infarction within 6 months;
* clinically significant cardiac arrhythmia
* Have active sign of herpes zoster
* Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.
* Patients with eczema, psoriasis, lichen simplex chronicus, with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
* Rash must cover \<10% of body surface area
* Disease is well controlled at baseline and requires stable use of low to mild potency topical corticosteroids for at least 4 weeks.
* No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 4 months.
* Immunomodulatory drugs or high-dose systemic steroids for concomitant or intercurrent conditions other than T-cell lymphoma within 7 days of registration.
However, stable dose of a low dose systemic systemic corticosteroid (≤10 mg prednisone equivalent per day) or stable dose of a low potency topical corticosteroid for at least 4 weeks prior to the registration is permitted. Subjects may receive intra-articular, intraocular, inhalation or nasal corticosteroids. Initiation of treatment with corticosteroids or increase in dose while on study is not permitted except for the treatment of adverse events.
* Patients who are planned to receive stem cell transplantation
* Has a known history of Human T-lymphotropic virus 1 (HTLV-1), or human immunodeficiency virus (HIV) (test to be performed within 21 days of registration if allowed by local legislation)
* Has known active Hepatitis B or Hepatitis C
* Note: patient will be eligible if:
* Negative hepatitis B surface antigen (HBsAg) test at screening
* Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening . The HBV DNA test will be performed only for patients who have a positive total HBcAb test.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pablo Luis Ortiz Romero
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario 12 De Octubre,Madrid, Spain
Richard Cowan
Role: PRINCIPAL_INVESTIGATOR
The Christie NHS Foundation Trust Manchester, UK
Jan Nicolay
Role: PRINCIPAL_INVESTIGATOR
UniversitaetsMedizin Mannheim, Mannheim, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Copenhagen - Rigshospitalet
Copenhagen, , Denmark
CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre
Bordeaux, , France
Assistance Publique Hopitaux Paris- APHP Nord - Univ De Paris Cite - Hop. Saint Louis
Paris, , France
UniversitaetsMedizin Mannheim
Mannheim, , Germany
Muehlenkreiskliniken Johannes Wesling Klinikum Minden
Minden, , Germany
Athens University - Attikon University General Hospital
Athens, , Greece
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, , Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Lazzaro
Torino, , Italy
Hospital De La Santa Creu I Sant Pau
Barcelona, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Hospital Universitario Puerta De Hierro
Madrid, , Spain
University Hospitals Birmingham NHS Foundation Trust (UHB) -Queen Elizabeth Medical Centre
Birmingham, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-1820-CLTF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.